• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC TO-C filed by Merus N.V.

    9/29/25 5:30:37 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRUS alert in real time by email
    SC TO-C 1 ss5386579_sctoc.htm TENDER OFFER STATEMENT

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE TO

    Tender Offer Statement Under Section 14(d)(1) or 13(e)(1)
    of the Securities Exchange Act of 1934

     

     

    Merus N.V.

    (Name of Subject Company)

     

    Genmab Holding II B.V.

     

    and

     

    Genmab A/S

    (Name of Filing Persons (Offerors))

     

    Common Share, nominal value €0.09 per share

    (Title of Class of Securities)

     

    N5749R100
    (CUSIP Number of Class of Securities)

     

    Greg Mueller
    Carl Jacobsens Vej 30

    2500 Valby

    Denmark

    +45 70 20 27 28

    (Name, Address and Telephone Number of Person Authorized
    to Receive Notices and Communications on Behalf of Filing Persons)

     

    Copy to:

     

    Clare O’Brien

    Derrick Lott
    Harald Halbhuber

    Allen Overy Shearman Sterling US LLP

    599 Lexington Avenue

    New York, NY 10022

    Telephone: +1 (212) 848-4000

     

     

    Calculation of Filing Fee

    Transaction Valuation Amount of Filing Fee
    N/A N/A

      

    ☐Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the Form or Schedule and date of its filing.

    Amount Previously Paid:  N/A Filing Party:  N/A
    Form or Registration No.:  N/A Date Filed:  N/A

     

    ☒Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

     

    Check the appropriate boxes below to designate any transactions to which the statement relates:

    ☒third-party tender offer subject to Rule 14d-1.
    ☐issuer tender offer subject to Rule 13e-4.
    ☐going-private transaction subject to Rule 13e-3.
    ☐amendment to Schedule 13D under Rule 13d-2.

     

    Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐

     

     
     

    SCHEDULE TO

    The pre-commencement communications filed under cover of this Tender Offer Statement on Schedule TO are being filed by Genmab A/S, a public limited liability company incorporated in Denmark (“Genmab”), pursuant to General Instruction D to Schedule TO related to a planned cash tender offer for all of the issued and outstanding common shares, nominal value €0.09 per share of Merus N.V., a public limited liability company (naamloze vennootschap) organized under the Laws of The Netherlands (the “Company”) pursuant to the Transaction Agreement, dated as of September 29, 2025, by and among Genmab, Genmab Holding II B.V., a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid) organized under the Laws of the Netherlands and a wholly-owned subsidiary of Genmab (“Purchaser”), and the Company.

     

    Additional Information

     

    The tender offer for the common shares of the Company (“Common Shares”) referenced in this announcement has not yet commenced. This announcement is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell Common Shares or any other securities, nor is it a substitute for the tender offer materials that Genmab and Purchaser will file or cause to be filed with the Securities and Exchange Commission (the “SEC”) upon the commencement of the tender offer. This communication may be deemed to be solicitation material in respect of the EGM Proposals (defined below). At the time the tender offer is commenced, Genmab and Purchaser will file or cause to be filed with the SEC a tender offer statement on Schedule TO (the “Tender Offer Statement”), and the Company will file with the SEC a solicitation/recommendation statement on Schedule 14D-9 (the “Solicitation/Recommendation Statement”), in each case, with respect to the tender offer. The Company also intends to file with the SEC a proxy statement on Schedule 14A in connection with an extraordinary general meeting of the Company’s shareholders, at which the Company’s shareholders will vote on certain proposed resolutions (the “EGM Proposals”) in connection with the transactions referenced herein, and will mail the definitive proxy statement and a proxy card to each shareholder of the Company entitled to vote at the extraordinary general meeting. THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS), THE SOLICITATION/RECOMMENDATION STATEMENT AND THE PROXY STATEMENT WILL CONTAIN IMPORTANT INFORMATION. SHAREHOLDERS OF THE COMPANY ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF COMMON SHARES SHOULD CONSIDER BEFORE MAKING ANY DECISION WITH RESPECT TO THE TENDER OFFER OR MAKING ANY VOTING DECISION. The tender offer for Common Shares will be made only pursuant to the Offer to Purchase, the Letter of Transmittal and related documents filed as a part of the Tender Offer Statement. The Tender Offer Statement (including the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents), as well as the Solicitation/Recommendation Statement, will be made available to all holders of Common Shares at no expense to them. The Tender Offer Statement and the Solicitation/Recommendation Statement will be made available for free at the SEC’s website at www.sec.gov. Copies of the documents filed by Genmab or Purchaser with the SEC will also be available free of charge on Parent’s website at https://www.genmab.com/investor-relations or by contacting Genmab’s investor relations department at [email protected]. Copies of the documents filed by the Company with the SEC will also be available free of charge on the Company’s website at https://ir.merus.nl/ or by contacting the Company’s investor relations department at [email protected]. In addition, shareholders of the Company may obtain free copies of the tender offer materials by contacting the information agent for the tender offer that will be named in the Tender Offer Statement.

     

     
     

     

    Forward-looking Statements

     

    This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Statements in this Company Announcement that are forward looking may include, but are not limited to, statements regarding the benefits of the proposed transaction; the development plan, regulatory approval, data release timing, commercial launch timing and revenue potential of petosemtamab; the expected timing of the closing of the proposed transaction; and Genmab’s expectations regarding financing the proposed transaction, de-levering and timing of new drug launches. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, the occurrence of any event, change or other circumstance that could give rise to the right of Genmab or the Company or both of them to terminate the transaction agreement, including circumstances requiring a party to pay the other party a termination fee pursuant to the transaction agreement; the failure to obtain applicable regulatory approvals or clearances or the Company shareholder approval in a timely manner or otherwise; the risk that the proposed transaction may not close in the anticipated timeframe or at all due to one or more of the other closing conditions to the proposed transaction not being satisfied or waived; the risk that there may be unexpected costs, charges or expenses resulting from the proposed transaction; risks related to the ability of Genmab to successfully integrate the Company’s business with Genmab’s existing businesses and achieve the expected benefits of the proposed transaction within the expected timeframes or at all and the possibility that such integration may be more difficult, time consuming or costly than expected; risks that the proposed transaction disrupts Genmab’s or the Company’s current plans and operations; risks related to disruption of each company’s management’s time and attention from ongoing business operations due to the proposed transaction; continued availability of capital and financing and rating agency actions; the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Genmab’s and/or the Company’s securities or operating results; the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Genmab and the Company to retain and hire key personnel, and to maintain relationships with their respective business partners and on their respective operating results and businesses generally; risks typically associated with conducting clinical trials, including the risk that additional clinical trials testing the Company’s products may not be successful; the risk that the Company’s products may not be approved on expected timelines or at all; the risk of litigation that could be instituted against Genmab or its directors, managers or officers and/or regulatory actions related to the proposed transaction, including the effects of any outcomes related thereto; risks related to unpredictable and severe or catastrophic events, including but not limited to acts of terrorism, war or hostilities, cyber-attacks, or the impact of any pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide on Genmab’s and/or the Company’s business, financial condition and results of operations, as well the response thereto by each company’s management; and other business effects, including the effects of industry, market, economic, political or regulatory conditions. Also, actual results or performance of Genmab and the Company may differ materially from any future results or performance expressed or implied by such statements for a number of additional reasons as described in Genmab’s and the Company’s respective filings with the SEC, including those included in Genmab’s most recent Annual Report on Form 20-F, which is available at www.genmab.com and www.sec.gov and those included in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which is available at https://ir.merus.nl/ and www.sec.gov. Neither Genmab nor the Company undertakes any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

     

    ***

     

     

     
     

     

    Item 12.Exhibits.
    (a)(5)(a)Company Announcement, dated September 29, 2025: Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
    (a)(5)(b)Genmab investor call slides, dated September 29, 2025
    (a)(5)(c)Social Media posts of Genmab and Jan G.J. van de Winkel, President and Chief Executive Officer of Genmab, dated September 29, 2025
    (a)(5)(d)Investor Relations call transcript, dated September 29, 2025

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $MRUS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRUS

    DatePrice TargetRatingAnalyst
    9/17/2025$112.00Overweight
    Barclays
    8/25/2025$90.00Buy
    Alliance Global Partners
    2/13/2025$84.00Overweight
    Piper Sandler
    2/7/2025$91.00Overweight
    Wells Fargo
    11/21/2024$73.00Buy
    Goldman
    10/24/2024$72.00Buy
    UBS
    3/28/2024$69.00Buy
    Truist
    3/4/2024$42.00 → $65.00Buy
    Needham
    More analyst ratings

    $MRUS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Merus with a new price target

    Barclays initiated coverage of Merus with a rating of Overweight and set a new price target of $112.00

    9/17/25 8:02:58 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners initiated coverage on Merus with a new price target

    Alliance Global Partners initiated coverage of Merus with a rating of Buy and set a new price target of $90.00

    8/25/25 7:58:18 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Merus with a new price target

    Piper Sandler initiated coverage of Merus with a rating of Overweight and set a new price target of $84.00

    2/13/25 8:09:56 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 6, 2024 - FDA Roundup: December 6, 2024

    For Immediate Release: December 06, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA published the draft guidance, “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics,” which proposes updates to certain agency policies and procedures regarding accelerated approval. Topics addressed by this

    12/6/24 3:09:02 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    SEC Filings

    View All

    SEC Form SC TO-C filed by Merus N.V.

    SC TO-C - Merus N.V. (0001651311) (Subject)

    9/29/25 5:30:37 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC14D9C filed by Merus N.V.

    SC14D9C - Merus N.V. (0001651311) (Subject)

    9/29/25 5:08:51 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Merus N.V.

    DEFA14A - Merus N.V. (0001651311) (Filer)

    9/29/25 5:06:49 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-st

    9/29/25 1:14:00 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, 2025, – Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus,

    9/29/25 1:08:26 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus to Present at the 2025 Wells Fargo Healthcare Conference

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) --  Merus N.V. (NASDAQ:MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 3:45 p.m. ET. The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event. About Mer

    8/28/25 8:00:00 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    COO & GC Silverman Peter B. exercised 25,000 shares at a strike of $24.43 and sold $1,500,000 worth of shares (25,000 units at $60.00) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    7/18/25 4:05:09 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COO & GC Silverman Peter B. exercised 23,500 shares at a strike of $18.61 and sold $1,292,500 worth of shares (23,500 units at $55.00) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    7/11/25 4:09:56 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    COO & GC Silverman Peter B. exercised 34,000 shares at a strike of $18.61 and sold $1,793,840 worth of shares (34,000 units at $52.76) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    6/24/25 4:00:05 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Financials

    Live finance-specific insights

    View All

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus, a clinical-stage biotechnology company with its late-st

    9/29/25 1:14:00 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

    Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab's portfolio Transaction anticipated to be accretive to EBITDA by end of 2029 Genmab to host a conference call today at 1:00 PM CEST / 12:00 PM BST / 7:00 AM EDT COPENHAGEN, Denmark; UTRECHT, The Netherlands; September 29, 2025, – Genmab A/S (NASDAQ: GMAB) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a transaction agreement pursuant to which Genmab intends to acquire all the shares of Merus,

    9/29/25 1:08:26 AM ET
    $GMAB
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

    -  63% response rate observed among 43 evaluable patients -  79% overall survival rate at 12-months; 9 months median progression-free survival -  Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be

    5/22/25 5:30:00 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRUS
    Leadership Updates

    Live Leadership Updates

    View All

    Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 01, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Fabian Zohren M.D., PhD as Chief Medical Officer (CMO) effective July 1, 2024. Andrew Joe, M.D. will step down from the CMO role and continue to serve as a Consultant for the next three months. In addition, effective July 1, Hui Liu, Ph.D., EVP, Chief Business Officer & Head of Merus U.S. is leaving Merus. The Company has initiated a search to find a replacement to head the business development f

    7/1/24 8:00:00 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Greg Perry as the Company's Chief Financial Officer (CFO). Additionally, Greg has been designated as the Company's principal financial officer, succeeding Bill Lundberg, M.D., in such role. In connection with his appointment as the Company's Chief Financial Officer, on June 14, 2023, Greg resigned from the Company's Board of Directors. "I am excited to welcome Greg as our CFO and look forward to drawing from his broad biotech e

    6/15/23 7:47:06 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a range of specialty markets, including oncology. "Shannon will be instrumental in advancing Merus' mission to become a commercial-stage company, further advancing the strategy for our lead clinical progr

    1/25/22 4:30:00 PM ET
    $INCY
    $MRUS
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $MRUS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Merus N.V.

    SC 13G/A - Merus N.V. (0001651311) (Subject)

    11/14/24 4:05:20 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Merus N.V.

    SC 13G/A - Merus N.V. (0001651311) (Subject)

    11/14/24 1:34:01 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Merus N.V.

    SC 13G/A - Merus N.V. (0001651311) (Subject)

    11/14/24 8:54:46 AM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care